Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

THOUSAND OAKS, Calif., Nov. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from the Open Label Study of Long TERm Evaluation Against LDL-C (OSLER) trial, a long-term controlled 52-week safety and efficacy study, that showed monthly treatment with evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood1, was not associated with a major increase in adverse events (AEs) versus standard of care (SOC) and produced mean LDL-C reductions of 52 percent in combination with SOC in patients with high cholesterol. These data from the first 52-week study of a PCSK9 inhibitor were presented for the first time today in a Clinical Science: Special Reports session at the American Heart Association (AHA) Scientific Sessions 2013 in Dallas and simultaneously published in Circulation.

According to the Centers for Disease Control and Prevention, more than 71 million American adults have high LDL-C.2 Elevated LDL-C is recognized as a major risk factor for cardiovascular (CV) disease, which is the number one cause of death worldwide, claiming more lives each year than cancer, chronic lower respiratory disease and accidents combined.3-5

"Phase 2 findings from OSLER, the first reported 52-week evaluation of a PCSK9 inhibitor, are encouraging and suggest evolocumab may be a promising option to treat hyperlipidemia in a range of at-risk patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We look forward to Phase 3 results from our PROFICIO clinical program evaluating the safety and efficacy of two distincti
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Agnition announced today that it will be ... for the first time at 7:30 a.m. CST March ... explore the extremely important role soil microbes perform in ... Microbial Catalystâ„¢ technology that enhances soil and plant health ... air again on April 28. , A biochemist at ...
(Date:3/25/2015)... The surging prevalence of internet ... social media growth, with over 50% of the ... networking. Insurance companies are making use of social ... promote a diversity of their services and products. ... social networking services as part of sales and ...
(Date:3/25/2015)... Accelovance, a therapeutically focused contract research organization ... Research Organization" at the upcoming Vaccine Industry Excellence (ViE) ... This is the eighth consecutive year Accelovance has ... for "Best Contract Research Organization" in 2009, 2010, and ... "We,re excited to be a finalist for ...
(Date:3/25/2015)... , March 25, 2015  Point-of-Care Partners, ... management consulting firm, has launched the ePrescribing State ... simplify tracking of ePrescribing regulatory requirements in all ... ePrescribing regulatory landscape continues to change rapidly, so ... what the industry, and ultimately patients, need," said ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... New York, NY (February 13, 2013) For consumers of the ... healthit may be hard to believe that there is such ... of salt. But Charles Zuker, PhD, and colleagues at ... high concentrations of salt (think seawater levels, not potato chips), ...
... Alberta study shows that busy beavers are helping Canada geese get ... nesting. Ponds in Alberta where beavers were active tended to ... better chance at reproductive success, according to the study, published recently ... to link beavers to early season nesting habits of Canada geese ...
... chemistry in romance-inspired classics like Mimi,s aria from La Bohme, ... and that young lady pining for her man with "O ... in ACS, Journal of Chemical Education , however, focuses ... that intertwines famous operatic plots. Joo Paulo Andr ...
Cached Biology News:Scientists discover how animals taste, and avoid, high salt concentrations 2Scientists discover how animals taste, and avoid, high salt concentrations 3
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 250 units polymerase, 1.25 ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: